Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion Original Article

Purpose: To re zunrah injection C C,u Nlacular Edema Secondary In Branch Retinal :kne.s,s and visual Kull lianges alter intravitreal ndary to branch retinal vein occlusion. Method: In Illis retrospe tine study, 15 eves of 15 patients ulltcth I A vastini injection for til xcnlar edema secondary to branch re Eves with br,tinch retin;iI arid pi:.)stimection optical coherens tomography (CT) measures and fovea] thickness were included in die study. All eyes received at kast 3 intravitreal my hev. cizuI fah monthly. Main outcome measure were Early Treatment Diabet Study (El DRS) Fisual acuity and fovea! thickness chanves, and complications, Results: Mean follow-up was 4.8 +/- 1.7 Its. Mean loveal 493.20 +/- 04,77 rum at baseline. 241,38 +/- 16,02 mm to 1 month. 253.60 +/- 109.03 min ai min at 3 months. 276.30 +/- 00.20 rum at tr months. Mean decrease its I dud. tiN - at postirnect nth.; I. 2. 3. and ( rp <0.0I}. Mean ETDRS; se ores iSnclIcni were 55,57 I -1,9d "t at - (i9,47+9,93 i.10/5 r 72.1.31-N,7.4 121)/4(.0 at 2 months, 72,08 +/- 9,56 120/40) at 3 mona,;, and months. change in Ell* S letters from baseline to months I. 2, 3, and r) ware cr(1.1.H I. Vitreous inflammation was 461.tscryt!t1 in one Patient. Conclusion: Inuziviircd1 INyaclzuniah injection for macular edema sect In cx'cl'tl lnl was effective and safe al early period. Further studies. with a *I.T;, to f patients are required.